<DOC>
	<DOCNO>NCT00429494</DOCNO>
	<brief_summary>Primary Objectives : - To determine effectiveness 3-month depot leuprolide induce maintain secondary amenorrhea patient undergo hematopoietic stem cell transplantation . - To determine incidence regain ovarian function manifest spontaneous restoration menstruation normalization hormonal level patient transplantation discontinuation long-acting leuprolide .</brief_summary>
	<brief_title>GnRH Analogue Ovarian Function Preservation Hematopoietic Stem Cell Transplantation Patients</brief_title>
	<detailed_description>All participant study schedule hematopoietic stem cell transplantation The University Texas ( UT ) MD Anderson Cancer Center . Within two month transplantation , participant medical history , physical exam , blood test ovarian function platelet count . Participants also need gynecologic exam within one year transplantation . Participants eligible receive first dose leuprolide injection either shoulder muscle thigh muscle first clinic visit . Participants low platelet count give platelet transfusion injection . Participants go transplantation schedule . Three month first dose injection participant another clinic visit blood test ovarian function perform . A second dose leuprolide give injection muscle visit . Again , patient low platelet count time , platelet transfusion give patient injection . Participants give checklist sheet record side effect effect leuprolide . Three month last dose injection , patient option start take resume oral contraceptive pill . Those choose take resume oral contraceptive pill follow observed return menstrual monthly cycle . Those choose take resume oral contraceptive pill , stop take oral contraceptive pill period 3-6 month start 1 year transplantation u assess ovarian function . During period follow observation return menstruation , participant see every two month either clinic hospital admit . Participants fill questionnaire menstrual history visit . They take 15 minute complete . Blood test ovarian function also do visit . This investigational study . The drug use study commercially available approve FDA use prostate cancer patient . Its use study investigational . About seventy-five patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Amenorrhea</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Menopause , Premature</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Hematopoietic stem cell transplantation candidate . Postmenarche female less 40 year old . Premenopausal start transplantation , start oral contraceptive pill . Folliclestimulating hormone ( FSH ) less equal 20 IU/L Luteinizing hormone ( LH ) less equal 20 IU/L within 1 week initiation injection ovarian status determine Gynecology Oncology Service . Agree stop oral contraceptive pill period 36 month start 1 year posttransplant Breast cancer Ovarian cancer Pregnancy Hypersensitivity Gonadotropinreleasing hormone ( GnRH ) analog</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>GnRH Analogue</keyword>
	<keyword>Gonadotropin-releasing hormone analogue</keyword>
	<keyword>GnRH-a</keyword>
	<keyword>Ovarian Function</keyword>
	<keyword>Fertility</keyword>
	<keyword>Leuprolide Acetate</keyword>
	<keyword>Lupron Depot</keyword>
	<keyword>premature ovarian failure</keyword>
	<keyword>POF</keyword>
	<keyword>Abnormal suppression menstruation</keyword>
	<keyword>absence menstruation</keyword>
</DOC>